In nano-technology, characterised by means of convergent technology and exponential growth in know-how, startups have transitioned from mere business vehicles to vital catalytic architectures for scientific frontier expansion. This study posits that the unique structural agility, risk tolerance, and undertaking-driven consciousness of startups allow them to operate as de-risking dealers for excessive-uncertainty clinical exploration, bridging the critical gap between essential research and industrialized innovation. We introduce the idea of translational plasticity, a startup's ability to concurrently navigate the abstract good judgment of scientific discovery and the concrete constraints of market application, as the vital determinant of its impact. This dynamism is operationalized by three dynamic capabilities: epistemic arbitrage (interpreting and synthesizing fragmented scientific knowledge), infrastructural symbiosis (using open-source and institutional R&D platforms), and ethical foresight (pre-emptively governing the societal aspects of nano-scale innovations). Based on a comparative study of startups of quantum computing and synthetic biology, this paper shows that startups are no longer outputs of the research establishment but have become generators of input and are actively reshaping scientific questions through designed artifacts and data-driven knowledge. It introduces a new paradigm of science policy and posits that supporting high-science startups is not an economic development policy but a first-order imperative of sustaining the vitality, relevance, and velocity of the very scientific enterprise of the 21st century.